David Keeney

2.0k total citations
24 papers, 1.7k citations indexed

About

David Keeney is a scholar working on Molecular Medicine, Molecular Biology and Pollution. According to data from OpenAlex, David Keeney has authored 24 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Medicine, 8 papers in Molecular Biology and 8 papers in Pollution. Recurrent topics in David Keeney's work include Antibiotic Resistance in Bacteria (13 papers), Pharmaceutical and Antibiotic Environmental Impacts (6 papers) and Bacterial Genetics and Biotechnology (4 papers). David Keeney is often cited by papers focused on Antibiotic Resistance in Bacteria (13 papers), Pharmaceutical and Antibiotic Environmental Impacts (6 papers) and Bacterial Genetics and Biotechnology (4 papers). David Keeney collaborates with scholars based in United States, Canada and China. David Keeney's co-authors include Alexey Ruzin, Patricia A. Bradford, B A Rasmussen, M Visalli, Youjun Yang, Karen Bush, David N. Frick, Angela M. Lam, Ellen Murphy and Fionnuala McAleese and has published in prestigious journals such as Journal of Biological Chemistry, Applied and Environmental Microbiology and Hepatology.

In The Last Decade

David Keeney

24 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Keeney United States	19	942	620	383	371	351	24	1.7k
Hideto Tsujimoto Japan	9	1.1k 1.2×	699 1.1×	353 0.9×	128 0.3×	218 0.6×	10	1.4k
Beibei Liang China	20	800 0.8×	619 1.0×	243 0.6×	207 0.6×	389 1.1×	59	1.7k
Dijun Du United Kingdom	16	1.2k 1.2×	1.1k 1.7×	326 0.9×	211 0.6×	320 0.9×	22	2.3k
Govindan Rajamohan India	16	693 0.7×	482 0.8×	166 0.4×	192 0.5×	282 0.8×	29	1.1k
Nicola Franceschini Italy	21	1.2k 1.3×	685 1.1×	391 1.0×	226 0.6×	457 1.3×	68	1.7k
Mei‐Ling Han Australia	26	673 0.7×	888 1.4×	309 0.8×	129 0.3×	146 0.4×	67	1.8k
Nobuhisa Masuda Japan	21	1.4k 1.5×	1.2k 2.0×	544 1.4×	150 0.4×	381 1.1×	39	2.4k
Roger Léger United States	16	981 1.0×	735 1.2×	443 1.2×	115 0.3×	122 0.3×	19	1.6k
B Jaurin Sweden	20	845 0.9×	992 1.6×	333 0.9×	202 0.5×	225 0.6×	24	1.8k
M Bogaki Japan	7	1.1k 1.1×	867 1.4×	553 1.4×	111 0.3×	153 0.4×	8	1.7k

Countries citing papers authored by David Keeney

Since Specialization

Citations

This map shows the geographic impact of David Keeney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Keeney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Keeney more than expected).

Fields of papers citing papers by David Keeney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Keeney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Keeney. The network helps show where David Keeney may publish in the future.

Co-authorship network of co-authors of David Keeney

This figure shows the co-authorship network connecting the top 25 collaborators of David Keeney. A scholar is included among the top collaborators of David Keeney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Keeney. David Keeney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kodali, Srinivas, Zheng-Hui Li, David Keeney, et al.. (2024). Preclinical validation of an Escherichia coli O-antigen glycoconjugate for the prevention of serotype O1 invasive disease. Microbiology Spectrum. 12(6). 2 indexed citations

Scully, Ingrid L., Yekaterina Timofeyeva, David Keeney, et al.. (2015). Demonstration of the preclinical correlate of protection for Staphylococcus aureus clumping factor A in a murine model of infection. Vaccine. 33(41). 5452–5457. 31 indexed citations

Jones, C. Hal, Margareta Tuckman, David Keeney, Alexey Ruzin, & Patricia A. Bradford. (2008). Characterization and Sequence Analysis of Extended-Spectrum-β-Lactamase-Encoding Genes from Escherichia coli, Klebsiella pneumoniae , and Proteus mirabilis Isolates Collected during Tigecycline Phase 3 Clinical Trials. Antimicrobial Agents and Chemotherapy. 53(2). 465–475. 53 indexed citations

Wright, Steven J., Jeremy D. Semrau, & David Keeney. (2008). Microbial Fouling of a Reverse Osmosis Municipal Water Treatment System. Water Environment Research. 80(8). 703–707. 1 indexed citations

Keeney, David, Alexey Ruzin, & Patricia A. Bradford. (2007). RamA, a Transcriptional Regulator, and AcrAB, an RND-Type Efflux Pump, are Associated with Decreased Susceptibility to Tigecycline in Enterobacter cloacae. Microbial Drug Resistance. 13(1). 1–6. 87 indexed citations

Ruzin, Alexey, David Keeney, & Patricia A. Bradford. (2007). AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus–Acinetobacter baumannii complex. Journal of Antimicrobial Chemotherapy. 59(5). 1001–1004. 192 indexed citations

Keeney, David, Alexey Ruzin, Fionnuala McAleese, Ellen Murphy, & Patricia A. Bradford. (2007). MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. Journal of Antimicrobial Chemotherapy. 61(1). 46–53. 127 indexed citations

Gilbert, A., Amedeo Failli, Youjun Yang, et al.. (2006). Pyrazolidine-3,5-diones and 5-Hydroxy-1H-pyrazol-3(2H)-ones, Inhibitors of UDP-N-acetylenolpyruvyl Glucosamine Reductase. Journal of Medicinal Chemistry. 49(20). 6027–6036. 85 indexed citations

Yang, Youjun, Anatoly Severin, Rajiv Chopra, et al.. (2006). 3,5-Dioxopyrazolidines, Novel Inhibitors of UDP- N - Acetylenolpyruvylglucosamine Reductase (MurB) with Activity against Gram-Positive Bacteria. Antimicrobial Agents and Chemotherapy. 50(2). 556–564. 68 indexed citations

10.

Lee, Sung-Woo, David Keeney, Dong‐Hee Lim, Alan A. DiSpirito, & Jeremy D. Semrau. (2006). Mixed Pollutant Degradation by Methylosinus trichosporium OB3b Expressing either Soluble or Particulate Methane Monooxygenase: Can the Tortoise Beat the Hare?. Applied and Environmental Microbiology. 72(12). 7503–7509. 78 indexed citations

11.

Begley, Lesa, David Keeney, Ben Beheshti, et al.. (2005). Concordant copy number and transcriptional activity of genes mapping to derivative chromosomes 8 during cellular immortalization in vitro. Genes Chromosomes and Cancer. 45(2). 136–146. 16 indexed citations

12.

Antane, Schuyler, Craig E. Caufield, William Hu, et al.. (2005). Pulvinones as bacterial cell wall biosynthesis inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(1). 176–180. 58 indexed citations

13.

Gong, Qiuming, David Keeney, Maurizio Molinari, & Zhengfeng Zhou. (2005). Degradation of Trafficking-defective Long QT Syndrome Type II Mutant Channels by the Ubiquitin-Proteasome Pathway. Journal of Biological Chemistry. 280(19). 19419–19425. 96 indexed citations

14.

Ruzin, Alexey, M Visalli, David Keeney, & Patricia A. Bradford. (2005). Influence of Transcriptional Activator RamA on Expression of Multidrug Efflux Pump AcrAB and Tigecycline Susceptibility in Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 49(3). 1017–1022. 168 indexed citations

15.

Lam, Angela M., David Keeney, & David N. Frick. (2003). Two Novel Conserved Motifs in the Hepatitis C Virus NS3 Protein Critical for Helicase Action. Journal of Biological Chemistry. 278(45). 44514–44524. 56 indexed citations

16.

Haney, Steven A., David Keeney, Lei Chen, et al.. (2003). Increased retention of functional fusions to toxic genes in new two-hybrid libraries of the E. coli strain MG1655 and B. subtilis strain 168 genomes, prepared without passaging through E. coli. BMC Genomics. 4(1). 36–36. 4 indexed citations

17.

Frick, David N., Andy K.M. Lam, & David Keeney. (2003). 392 Two novel conserved motifs in the hepatitis C virus NS3 protein critical for helicase action. Hepatology. 38. 349–349. 1 indexed citations

18.

Haney, Steven A., et al.. (2001). Genetic Analysis of the Escherichia coli FtsZ·ZipA Interaction in the Yeast Two-hybrid System. Journal of Biological Chemistry. 276(15). 11980–11987. 111 indexed citations

19.

Yang, Youjun, et al.. (1999). Kinetic Properties and Metal Content of the Metallo-β-lactamase CcrA Harboring Selective Amino Acid Substitutions. Journal of Biological Chemistry. 274(22). 15706–15711. 42 indexed citations

20.

Rasmussen, B A, et al.. (1996). Characterization of IMI-1 beta-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae. Antimicrobial Agents and Chemotherapy. 40(9). 2080–2086. 175 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact